All News

Diana Violanti, PharmD, and Pamela S. Moore, PharmD, BCGP, discuss the nuanced use of anticholinergic agents for managing terminal secretions at end of life, highlighting practical considerations, timing, safety concerns such as delirium, and the limited yet evolving evidence supporting their role in palliative care.

Cardinal Health is investing in cold chain logistics and packaging solutions to expedite the delivery of novel therapies from FDA approval to patient access.

As evidence grows for psilocybin-assisted therapy’s effectiveness in treating mental health and addiction, efforts are increasingly focused on ensuring equitable access—particularly for underserved communities disproportionately affected by systemic barriers and public health crises.

Currently, the treatment is undergoing evaluation in a 3-part clinical trial to determine its safety, efficacy, and pharmacokinetics in patients with recurrent advanced/metastatic cancers.

New trials reveal xanomeline and trospium effectively alleviate schizophrenia symptoms, offering a novel treatment option with minimal adverse effects.

New research highlights the need for evidence-based buspirone use in psychiatric settings, revealing high off-label prescriptions and suboptimal dosing practices.

In chronic hepatitis B (CHB) mouse models, the ferritin nanoparticle-preS1 (ferritin-NP-preS1) with small interfering RNA (siRNA) showed 100% and sustained serum HBsAg over an approximate 11-month period.

Despite benefits for reducing drug costs, community oncology practices face the unintended consequences of the IRA.

Jonas Congelli, RPh, discusses how limited distribution networks and medically integrated pharmacies can improve access, continuity, and quality of oncology care—particularly in underserved areas—while addressing systemic barriers posed by traditional distribution models and pharmacy benefit managers.

Pharmacists are on the front lines of the outbreak, making them well-positioned to educate and counsel patients with vaccine hesitancy.

Ravi Parikh, MD, MPP, FACP, discusses how artificial intelligence is transforming oncology pharmacy by accelerating drug development, enhancing clinical decision-making, supporting value-based care, and raising critical questions about ethics, regulation, and data integrity.

A survey showed that 92% of Americans are open to treatments that would slow disease progression.

Research shows comprehensive medication reviews enhance medication adherence in those with type 2 diabetes, highlighting pharmacists' vital role in improving health outcomes.

Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses how looming tariffs, vaccine misinformation, and rising drug costs are straining public health pharmacy efforts, while also sparking new opportunities for innovation, collaboration, and community-centered care amid uncertainty.

Research reveals a significant link between maternal anemia and increased risk of congenital heart defects in infants, highlighting the need for effective prevention strategies.

New trial results highlight intravenous immunoglobulin (IVIG) 10% as an effective rescue treatment for relapsing chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), enhancing patient care and pharmacist involvement in management.

Paula E. Voinescu, PhD, MD, emphasized the need for additional research in this area, noting it is both “surprising and upsetting.”

The condition, which is common in patients with chronic kidney disease (CKD), is characterized by skin lesions and currently has no curative treatment.

In the treatment of metabolic dysfunction-associated steatohepatitis (MASH), engineered extracellular vesicles helped mitigate disease progression and did not compromise bone density.

Specialty pharmacies must develop comprehensive health equity programs that address diverse patient needs.

Liposomal annamycin demonstrates broad synergistic activity with multiple FDA-approved chemotherapies across hematologic and solid tumors in preclinical models, offering a promising and safer combination strategy for resistant and high-risk cancers.

In clinical trials, the dihydroergotamine (DHE) nasal powder had favorable safety profiles and rapid pain relief in patients with migraine with or without aura.

The American Lung Association is raising awareness about updated pneumococcal vaccine guidelines, emphasizing prevention and patient education for at-risk populations.

Cimerli offers a promising biosimilar treatment for age-related macular degeneration, enhancing vision preservation with its effective VEGF inhibition.

New research shows adults with RSV-ARI may face significantly higher mortality and health complications, emphasizing the need for targeted vaccination strategies.